European Union - English - EMA (European Medicines Agency)

merck sharp & dohme b.v. - ertugliflozin l-pyroglutamic acid, metformin hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients not adequately controlled on their maximally tolerated dose of metformin alonein patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetesin patients already being treated with the combination of ertugliflozin and metformin as separate tablets.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

merck sharp & dohme (malaysia) sdn bhd - ertuglifozin l-pyroglutamic acid; metformin hydrochloride -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

merck sharp & dohme (malaysia) sdn bhd - ertuglifozin l-pyroglutamic acid; metformin hydrochloride -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

merck sharp & dohme (malaysia) sdn bhd - ertuglifozin l-pyroglutamic acid; metformin hydrochloride -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

merck sharp & dohme (malaysia) sdn bhd - ertuglifozin l-pyroglutamic acid; metformin hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - metformin hydrochloride, quantity: 500 mg; ertugliflozin pyroglutamic acid, quantity: 9.713 mg (equivalent: ertugliflozin, qty 7.5 mg) - tablet, film coated - excipient ingredients: crospovidone; sodium lauryl sulfate; microcrystalline cellulose; carnauba wax; povidone; magnesium stearate; titanium dioxide; hypromellose; hyprolose; iron oxide red - msd-ertugliflozin-metformin (ertugliflozin and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both ertugliflozin and metformin is appropriate. [see 5.1 pharmacodynamic properties, clinical trials and 4.2 dose and method of administration]

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - metformin hydrochloride, quantity: 500 mg; ertugliflozin pyroglutamic acid, quantity: 3.238 mg (equivalent: ertugliflozin, qty 2.5 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; carnauba wax; povidone; sodium lauryl sulfate; magnesium stearate; crospovidone; titanium dioxide; hypromellose; hyprolose; iron oxide red - msd-ertugliflozin-metformin (ertugliflozin and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both ertugliflozin and metformin is appropriate. [see 5.1 pharmacodynamic properties, clinical trials and 4.2 dose and method of administration]

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - metformin hydrochloride, quantity: 1000 mg; ertugliflozin pyroglutamic acid, quantity: 9.713 mg (equivalent: ertugliflozin, qty 7.5 mg) - tablet, film coated - excipient ingredients: sodium lauryl sulfate; povidone; magnesium stearate; crospovidone; carnauba wax; microcrystalline cellulose; titanium dioxide; hypromellose; hyprolose; iron oxide red - msd-ertugliflozin-metformin (ertugliflozin and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both ertugliflozin and metformin is appropriate. [see 5.1 pharmacodynamic properties, clinical trials and 4.2 dose and method of administration]

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - metformin hydrochloride, quantity: 1000 mg; ertugliflozin pyroglutamic acid, quantity: 3.238 mg (equivalent: ertugliflozin, qty 2.5 mg) - tablet, film coated - excipient ingredients: sodium lauryl sulfate; crospovidone; magnesium stearate; povidone; carnauba wax; microcrystalline cellulose; titanium dioxide; hypromellose; hyprolose; iron oxide red - msd-ertugliflozin-metformin (ertugliflozin and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both ertugliflozin and metformin is appropriate. [see 5.1 pharmacodynamic properties, clinical trials and 4.2 dose and method of administration]

Israel - English - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - ertugliflozin (l-pga); metformin hydrochloride - film coated tablets - metformin hydrochloride 1000 mg; ertugliflozin (l-pga) 2.5 mg - metformin and ertugliflozin - segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:• in patients not adequately controlled on their maximally tolerated dose of metformin alone• in patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetes • in patients already being treated with the combination of ertugliflozin and metformin as separate tablets.